Aft Pharmaceuticals Ltd. · NZX:AFT
Aft Pharmaceuticals — ASX Small Cap Conference 2025
17 slides from Aft Pharmaceuticals's conference presentation, Mar 26, 2025
Slide 1: ASX Small Cap Conference Presentation
For personal use only ASX SMALL CAP CONFERENCE PRESENTATION Dr Hartley Atkinson Managing Director SYDNEY, 26 MARCH 2025
Slide 2: Important Notice
Important Notice For personal use only This presentation has been prepared by AFT Pharmaceuticals Limited (“AFT”), to provide a general overview of the performance of AFT. It is not prepared for any other purpose and must not be provided to any person other than the intended recipient. This presenta
Slide 3: Agenda
Agenda For personal use only • Business Overview & Highlights • Outlook & Pipeline • Questions • Appendices: Further Information Dr Hartley Atkinson Managing Director and Co-Founder AFT PHARMACEUTICALS WORKING TO IMPROVE YOUR HEALTH 3
Slide 4: AFT Pharmaceuticals (AFP:AX) at a Glance
AFT Pharmaceuticals (AFP:AX) at a Glance An established high-growth Australasian Pharmaceutical Company For personal use only ESTABLISHED GROWING ANZ EXPANDING AFT INTERNATIONAL BUSINESS FOOTPRINT • FY24 Total Sales $195.4M (5yr CAGR 18%) • UK & Europe • ANZ Sales $156.9m • Canada & USA OTCs • Growt
Slide 5: Accelerating Revenues and Investment for Future Growth
Accelerating Revenues and Investment for Future Growth HIGHLIGHTS • Upcoming product launches and international footprint expansion are anticipated to drive topline momentum. Revenues in the second half are anticipated to accelerate with the increased commercialization activities and market stabiliz
Slide 6: Revenue Growth Across All Markets
Revenue Growth Across All Markets AUSTRALIAN REVENUE NEW ZEALAND REVENUE $108.2 For personal use only $48.7 $100.0 $94.1 $50.0 $44.2 $76.7 $40.0 $35.1 $80.0 $68.3 $65.5 $30.1 $30.5 $26.0 $61.4 $30.0 $NZM $60.0 NZ$M $20.0 $40.0 $22.7 $26.0 $50.8 $10.0 $20.0 $42.7 $- $- FY2020 FY2021 FY 2022 FY2023 FY
Slide 7: Financial strength and momentum following IPO
Financial strength and momentum following IPO • AFT has continued to balance long term income growth to steadily growing shareholder equity since FY19 while continually making investments to expand the portfolio through R&D and international footprint expansion For personal use only • Continue to de
Slide 8: AFT's Global Reach
AFT’s Global Reach Our medicines are now available in nearly 80 countries around the world For personal use only AFT PHARMACEUTICALS WORKING TO IMPROVE YOUR HEALTH 8
Slide 9: Expanding AFT's Global Footprint
Expanding AFT’s Global Footprint Opening new markets for our proprietary IP and in-licensed new products AFT PHARM USA • Selected OTC launches and coordinate licensees and distributors For personal use only AFT PHARM UK (70% AFT) • Launched Combogesic tablets and IV. Launching multiple products • A
Slide 10: Research and Development Investments Moving to Commercialisation
Research and Development Investments Moving to Commercialisation Several R&D projects have been completed and are moving to revenue generation For personal use only RESEARCH AND DEVELOPMENT EXPENSES* COMMERCIALISATION PROGRESSING 20 agreements under discussion following completion of 4 drug China de
Slide 11: A Strong Research and Development Pipeline
A Strong Research and Development Pipeline AFT’s positive cashflows have positioned the company well to undertake and secure research and development projects either alone or in partnership with others. In order of estimated timeline PROJECT PATENT PARTNERSHIP / APPLICATION For personal use only DER
Slide 12: Outlook: Positioned for Near Term Growth
Outlook: Positioned for Near Term Growth • AFT expects a strong recovery in the second half of the year, in line with prior years, assisted by: For personal use only • a strong program of new product launches especially in International markets • building momentum in the new markets • the resumption
Slide 13: Questions
For personal use only QUESTIONS
Slide 14: Appendix 1: History of AFT Pharmaceuticals
Appendix 1: History of AFT Pharmaceuticals For personal use only AFT was founded over 25 years ago by Dr Hartley and Marree Atkinson. Since then, AFT has remained an Atkinson-family controlled business and has grown organically into Australia and internationally The 2015 IPO raised funds to pursue a
Slide 15: Appendix 2: Australasian Product Portfolio
Appendix 2: Australasian Product Portfolio AFT has the #1 selling product (Maxigesic) in the Australian para-ibu1 combo pain relief. AFT’s portfolio includes a combination of over 150 proprietary, branded and generic products which address the following therapeutic areas: For personal use only Pain
Slide 16: Appendix 3: AFT Global Product Portfolio
Appendix 3: AFT Global Product Portfolio AFT is building the global presence of its proprietary and patented products through its network of licensees and distributors. For personal use only It continues the development of its portfolio of repurposed medicines: Maxigesic1, Pascomer, and Crystaderm P
Slide 17: For More Information
FOR MORE INFORMATION Dr Hartley Atkinson Managing Director For personal use only Email: [email protected] Malcolm Tubby Chief Financial Officer Email: [email protected] AFT Pharmaceuticals Limited Level 1, 129 Hurstmere Road Takapuna, Auckland 0622 New Zealand www.aftpharm.com